Effects of weifuchun tablet for chronic atrophic gastritis: A protocol for systematic review and meta-analysis.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
29 May 2020
29 May 2020
Historique:
entrez:
3
6
2020
pubmed:
3
6
2020
medline:
7
7
2020
Statut:
ppublish
Résumé
Chronic atrophic gastritis (CAG) is defined as an important precancerous disease in the development of gastric cancer. Early intervention of CAG is of great significance in reducing symptoms and blocking its progression to gastric cancer. Weifuchun (WFC) tablet is a classic Chinese patent medicine used to treat CAG. However, there is no systematic review related to WFC for atrophic gastritis published in English. we will conduct systematic review and meta-analysis to provide more evidence on the effectiveness and safety for clinical use of WFC. Three English database and 4 Chinese databases will be searched from its inception to April 2020. Two trained researchers will independently select the qualified studies for data extraction and assess the quality and risk of bias. Then the meta-analyses will be performed by using the RevMan 5.2 and stata 14.0. The heterogeneity of data will be investigated by Cochrane X and I tests. Sensitivity analysis will be conducted to evaluate the stability of the results. A funnel plot analysis and Egger's test will be drawn to assess the publication bias. Finally, we will use the Grading of Recommendations Assessment, Development and Evaluate system to evaluate the methodological quality. The results of our research will be published in a peer-reviewed journal. The conclusion of our systematic review will provide evidence to judge whether WFC is an effective intervention for patient with CAG. 10.17605/OSF.IO/2UTMB.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic atrophic gastritis (CAG) is defined as an important precancerous disease in the development of gastric cancer. Early intervention of CAG is of great significance in reducing symptoms and blocking its progression to gastric cancer. Weifuchun (WFC) tablet is a classic Chinese patent medicine used to treat CAG. However, there is no systematic review related to WFC for atrophic gastritis published in English. we will conduct systematic review and meta-analysis to provide more evidence on the effectiveness and safety for clinical use of WFC.
METHODS AND ANALYSIS
METHODS
Three English database and 4 Chinese databases will be searched from its inception to April 2020. Two trained researchers will independently select the qualified studies for data extraction and assess the quality and risk of bias. Then the meta-analyses will be performed by using the RevMan 5.2 and stata 14.0. The heterogeneity of data will be investigated by Cochrane X and I tests. Sensitivity analysis will be conducted to evaluate the stability of the results. A funnel plot analysis and Egger's test will be drawn to assess the publication bias. Finally, we will use the Grading of Recommendations Assessment, Development and Evaluate system to evaluate the methodological quality.
RESULTS
RESULTS
The results of our research will be published in a peer-reviewed journal.
CONCLUSION
CONCLUSIONS
The conclusion of our systematic review will provide evidence to judge whether WFC is an effective intervention for patient with CAG.
OSF REGISTRATION NUMBER
UNASSIGNED
10.17605/OSF.IO/2UTMB.
Identifiants
pubmed: 32481421
doi: 10.1097/MD.0000000000020374
pii: 00005792-202005290-00066
doi:
Substances chimiques
Drugs, Chinese Herbal
0
Tablets
0
weifuchun
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e20374Références
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012. Int J Cancer 2015;136:E359–86.
Correa P. A human model of gastric carcinogenesis. Cancer Res 1988;48:3554–60.
Ohata H, Kitauchi S, Yoshimura N, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004;109:138–43.
Du Y, Bai Y, Xie P, et al. Chronic gastritis in China: a national multi-center survey. BMC Gastroenterol 2014;14:21.
den Hollander WJ, Kuipers EJ. Current pharmacotherapy options for gastritis. Expert Opin Pharmacother 2012;13:2625–36.
Dai Y-K, Zhang Y-Z, Li D-Y, et al. The efficacy of Jianpi Yiqi therapy for chronic atrophic gastritis: A systematic review and meta-analysis. PLoS One 2017;12:e0181906.
Shu M, Jiang Z, Wang Y, et al. Clinical efficacy of weifuchun combined with retinoic acid on treatment of patients with PLGC and effect on expressions of gene Rb and C-erbB-2. Biomedical Research 2017;0:606–9.
Li H-Z, Wang H, Wang G-Q, et al. Treatment of gastric precancerous lesions with Weiansan. World J Gastroenterol 2006;12:5389–92.
Junxiang L, Jing C, Bin L, et al. Consensus on the diagnosis and treatment of integrated Chinese and Western medicine for chronic atrophic gastritis. Chinese Journal of Integrated Traditional and Western Medicine on Digestion 2018;26:121–31.
Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–58.
Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med 1992;116:78–84.
Sun X, Briel M, Walter SD, et al. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ 2010;340:c117.
Peters JL, Sutton AJ, Jones DR, et al. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol 2008;61:991–6.
Group GW. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490.
Gao K, Wu J. National trend of gastric cancer mortality in China (2003-2015): a population-based study. Cancer Commun (Lond) 2019;39:24.